InMode (STU:154) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:154 InMode Ltd STU:154
84 GF Score
Price €13.47
GF Value €16.95
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is InMode FFO per Share?

FFO per Share only applies to REITs.

STU:154
84GF Score
InMode Ltd STU:154
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is InMode (STU:154) Overvalued in 2026?

Based on GuruFocus' analysis, InMode stock appears to be undervalued. The current stock price of €13.47 is trading 20.5% below its estimated GF Value™ of €16.95. GuruFocus considers InMode to be Modestly Undervalued.

Key valuation signals for STU:154:

  • FFO per Share:
  • GF Value™: €16.95 vs. price of €13.47 (20.5% below fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the STU:154 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InMode Business Description

Other Exchanges INMD:USA
Address Sha’ar Yokneam, Tavor Building, P.O. Box 533, Yokneam, ISR, 2069206
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.
84GF Score

Get the complete analysis for STU:154

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.47
Price
€16.95
GF Value